{"title":"每日一次MMX美沙拉明治疗溃疡性结肠炎","authors":"W. Blonski, A. Buchner, G. Lichtenstein","doi":"10.4137/CGast.S4276","DOIUrl":null,"url":null,"abstract":"Mesalamine (5-ASA) has been the mainstay therapy of mild to moderate active ulcerative colitis both as an induction and maintenance treatment. Multimatrix system (MMX) 5-ASA is a recently developed formulation of 5-ASA allowing for slow and gradual release of 5-ASA throughout the entire colon. This review article discusses the structure, pharmacokinetics, efficacy and safety of this new 5-ASA formulation.","PeriodicalId":10382,"journal":{"name":"Clinical Medicine Insights. Gastroenterology","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CGast.S4276","citationCount":"2","resultStr":"{\"title\":\"Once-Daily MMX Mesalamine in the Management of Ulcerative colitis\",\"authors\":\"W. Blonski, A. Buchner, G. Lichtenstein\",\"doi\":\"10.4137/CGast.S4276\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mesalamine (5-ASA) has been the mainstay therapy of mild to moderate active ulcerative colitis both as an induction and maintenance treatment. Multimatrix system (MMX) 5-ASA is a recently developed formulation of 5-ASA allowing for slow and gradual release of 5-ASA throughout the entire colon. This review article discusses the structure, pharmacokinetics, efficacy and safety of this new 5-ASA formulation.\",\"PeriodicalId\":10382,\"journal\":{\"name\":\"Clinical Medicine Insights. Gastroenterology\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4137/CGast.S4276\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights. Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/CGast.S4276\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/CGast.S4276","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Once-Daily MMX Mesalamine in the Management of Ulcerative colitis
Mesalamine (5-ASA) has been the mainstay therapy of mild to moderate active ulcerative colitis both as an induction and maintenance treatment. Multimatrix system (MMX) 5-ASA is a recently developed formulation of 5-ASA allowing for slow and gradual release of 5-ASA throughout the entire colon. This review article discusses the structure, pharmacokinetics, efficacy and safety of this new 5-ASA formulation.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
